<DOC>
	<DOCNO>NCT00499135</DOCNO>
	<brief_summary>This phase I trial study side effect best way give sunitinib malate treat patient unresectable metastatic kidney cancer advance solid tumor . Sunitinib malate may stop growth tumor cell block blood flow tumor block enzyme need cell growth .</brief_summary>
	<brief_title>Sunitinib Malate Treating Patients With Unresectable Metastatic Kidney Cancer Other Advanced Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine pharmacodynamic change use functional imaging ( 3'-deoxy-3'- [ 18F ] fluorothymidine [ FLT ] -positron emission tomography [ PET ] /computed tomography [ CT ] scan ) patient unresectable metastatic clear cell renal cell carcinoma advance solid malignancy treat two different schedule sunitinib malate . II . Evaluate objective response patient treated drug . SECONDARY OBJECTIVES : I . Measure change plasma vascular endothelial growth factor ( VEGF ) level plasma hypoxia-inducible factor ( HIF ) 1-alpha level potential mechanism vascular endothelial growth factor receptor ( VEGFR ) tyrosine kinase inhibitor ( TKI ) failure rapid tumor growth follow VEGFR TKI withdrawal patient . II . Correlate pharmacokinetics drug response , unexpected toxicity , VEGF level , HIF1-alpha level , FLT-PET/CT scan change . OUTLINE : Patients assign 1 2 different treatment schedule sunitinib malate . SCHEDULE A : Patients receive sunitinib malate orally ( PO ) daily ( QD ) week 1-4 . Treatment repeat every 6 week absence disease progression unacceptable toxicity . SCHEDULE B : Patients receive sunitinib malate PO QD week 1 , 2 , 4 , 5 . Treatment repeat every 6 week absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Alovudine</mesh_term>
	<mesh_term>Dideoxynucleosides</mesh_term>
	<criteria>Patients must histologically cytologically confirm renal cell cancer ; solid malignancy ( exclude lymphoma ) metastatic unresectable standard curative therapy exist For renal cell cancer subset , component clear cell histology require Measurable disease , define &gt; = 1 unidimensionally measurable lesion &gt; = 20 mm conventional technique &gt; = 10 mm spiral CT scan Life expectancy &gt; 12 week Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Leukocytes &gt; = 3,000/mm^3 Absolute neutrophil count ( ANC ) &gt; = 1,500/mm^3 Platelet count &gt; = 100,000/mm^3 Hemoglobin &gt; = 9 g/dL Serum calcium = &lt; 12.0 mg/dL Total bilirubin normal Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 2.5 time upper limit normal ( ULN ) , unless subject liver metastasis , case AST ALT must = &lt; 5 x ULN Creatinine = &lt; 2 time ULN OR creatinine clearance &gt; = 40 mL/min patient creatinine level 2 x institutional normal All patient need willing undergo plan pharmacodynamic assessment , include serial PET imaging , plasma marker , pharmacokinetic sample Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation Ability understand willingness sign write informed consent document Patients chemotherapy , radiotherapy , experimental therapy major surgery within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover ( grade &lt; 1 baseline ) clinically significant adverse event due agent administer 4 week earlier ( alopecia fatigue exclude ) ; clinical significance determine investigator Patients may receive investigational agent No prior treatment antiVEGF agent allow History allergic reaction attribute compound similar chemical biologic composition sunitinib malate Patients QTc prolongation ( define QTc interval great 500 msec ) significant electrocardiogram ( ECG ) abnormality ( per investigator discretion ) exclude Patients poorly control hypertension ( systolic blood pressure 140 mm Hg high diastolic blood pressure 90 mm Hg high ) ineligible Patients condition ( e.g. , gastrointestinal tract disease result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease ) impair ability swallow retain sunitinib tablet exclude Patients follow condition exclude : Serious nonhealing wound , ulcer , bone fracture Abdominal fistula , gastrointestinal ( GI ) perforation , intraabdominal abscess within past 28 day Cerebrovascular accident ( CVA ) transient ischemic attack within 12 month prior study entry History myocardial infarction , cardiac arrhythmia , stable/unstable angina , symptomatic congestive heart failure , coronary/peripheral artery bypass graft stenting within past 12 month History pulmonary embolism within past 12 month Class III IV heart failure define New York Heart Association ( NYHA ) functional classification system Patients preexist thyroid abnormality unable maintain thyroid function normal range medication ineligible ; patient history hypothyroidism eligible provide currently euthyroid Patients know brain metastasis Patients uncontrolled intercurrent illness include , limited , ongoing active infection psychiatric illness/social situation would limit compliance study requirement ineligible Pregnant breastfeeding No concurrent therapeutic dos coumarinderivative anticoagulant , warfarin ; Concurrent dose = &lt; 2 mg/day allow prophylaxis thrombosis , Concurrent low molecular weight heparin allow provide prothrombin time ( PT ) international normalize ratio ( INR ) = &lt; 1.5 No concurrent agent proarrhythmic potential ( terfenadine , quinidine , procainamide , disopyramide , sotalol , probucol , bepridil , haloperidol , risperidone , indapamide , flecainide acetate ) Human immunodeficiency virus ( HIV ) positive patient combination antiretroviral therapy ineligible</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>